Immunotherapeutic Value of MAP1LC3C and Its Candidate FDA-Approved Drugs Identified by Pan-Cancer Analysis, Virtual Screening and Sensitivity Analysis.
- DOI
- 10.3389/fphar.2022.863856
- Published
- 2022
- Container
- Frontiers in pharmacology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fphar.2022.863856,
title = {Immunotherapeutic Value of MAP1LC3C and Its Candidate FDA-Approved Drugs Identified by Pan-Cancer Analysis, Virtual Screening and Sensitivity Analysis.},
author = {Zhang X and Li K and Zhong S and Liu S and Liu T and Li L and Han S and Zhai Q and Bao N and Shi X and Bao Y},
year = {2022},
journal = {Frontiers in pharmacology},
doi = {10.3389/fphar.2022.863856},
url = {https://doi.org/10.3389/fphar.2022.863856}
}RIS
TY - JOUR TI - Immunotherapeutic Value of MAP1LC3C and Its Candidate FDA-Approved Drugs Identified by Pan-Cancer Analysis, Virtual Screening and Sensitivity Analysis. AU - Zhang X AU - Li K AU - Zhong S AU - Liu S AU - Liu T AU - Li L AU - Han S AU - Zhai Q AU - Bao N AU - Shi X AU - Bao Y PY - 2022 JO - Frontiers in pharmacology DO - 10.3389/fphar.2022.863856 UR - https://doi.org/10.3389/fphar.2022.863856 ER -
APA
X, Z., K, L., S, Z., S, L., T, L., L, L., S, H., Q, Z., N, B., X, S., & Y, B. (2022). Immunotherapeutic Value of MAP1LC3C and Its Candidate FDA-Approved Drugs Identified by Pan-Cancer Analysis, Virtual Screening and Sensitivity Analysis.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2022.863856
Source records
- pubmed · retrieved 2026-09-25T23:19:33.103Z